MORGANTOWN, W.Va. – The WVU Cancer Institute Cellular Therapy Program was recently awarded its sixth consecutive Foundation for the Accreditation of Cellular Therapy (FACT) reaccreditation for blood and marrow transplant and first FACT accreditation for immune effector cell therapy (CAR-T).
FACT accreditation is the threshold for excellence in cellular therapy and demonstrates that the program has exceeded standards in patient care and laboratory services. This voluntary accreditation is based upon compliance with the most comprehensive standards in the field, verified by rigorous peer-reviewed inspections. Inspections are carried out by a team of inspectors who are qualified by training and experience and perform cellular therapy functions in their daily practice.
Accredited programs offer:
- experienced personnel who have undergone specialized training to understand and provide care for the unique needs of cellular therapy patients;
- policies and procedures in place for the safe administration of cellular therapy products that are required for optimum patient care outcomes; and
- processes guided by a robust quality management system.
The WVU Cancer Institute Cellular Therapy Program has been FACT accredited since 2002 and has been re-accredited every three years since. The Institute’s Cellular Therapy Program currently offers autologous and allogeneic transplants (peripheral blood, bone marrow, and cord) and five different CAR-T cells products for disease treatment.
Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a non-profit corporation co-founded by the International Society for Cellular Therapy and the American Society of Blood and Marrow Transplantation for the purposes of voluntary inspection and accreditation in the field of cellular therapy.
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.